Serina Therapeutics, Inc. filed a Form 8-K current report on November 12, 2026, announcing the release of its financial results for the quarter ended September 30, 2026.
Key Highlights
- Reporting period: Financial results cover the quarter ended September 30, 2026.
- Press release date: The company issued its financial results press release on November 12, 2026, furnished as Exhibit 99.1.
- Exchange listing: Common Stock, par value $0.0001 per share, trades under the symbol SER on NYSE American.
- Signatory: The filing was signed by Steve Ledger, Chief Executive Officer, on November 12, 2026.
- Filing limitation: The disclosed information is "not deemed to be 'filed'" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, according to the filing.
Serina Therapeutics Reports Q3 2026 Financial Results via Current Report
Serina Therapeutics, Inc. (NYSE American:SER), a Delaware-incorporated company headquartered at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806, filed a Form 8-K with the U.S. Securities and Exchange Commission on November 12, 2026. According to the filing, the report was submitted under Item 2.02, Results of Operations and Financial Condition, to announce the company's financial results for the quarter ended September 30, 2026.
The filing states that a press release containing those financial results was issued on November 12, 2026, and is furnished as Exhibit 99.1 to the current report. The filing further discloses that the information provided under Item 2.02 and in the press release "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference.
The company's Common Stock carries a par value of $0.0001 per share and is registered on NYSE American under the trading symbol SER, as stated on the cover page of the filing. The report was signed by Steve Ledger in his capacity as Chief Executive Officer. Serina Therapeutics holds Commission File Number 1-38519 and IRS Employer Identification Number 82-1436829. The filing does not indicate that Serina is an emerging growth company.
What Was Disclosed
Serina Therapeutics filed a Form 8-K on November 12, 2026, announcing its Q3 2026 financial results for the quarter ended September 30, 2026, through a furnished press release (Exhibit 99.1), signed by CEO Steve Ledger.




Please wait processing your request...